Sentiment Summary
Recent Events
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
The Q2 2026 earnings release scheduled for 2026-07-29, for which high importance is estimated due to typical market volatility surrounding quarterly results, is expected.
Q2 2026 earnings release is scheduled for July 16, 2026; a price impact of at least 5% is estimated based on historical volatility, scheduled.
Final dividend of HKD 0.20 per share ex-dividend on July 3, 2026; standard corporate action with minor price adjustment scheduled.
Ex-dividend date for the 2025 final dividend of HK$0.15 per share, which was announced on March 25, 2026. The payment date is July 15, 2026.
Ex-dividend date (2026-06-19) for a proposed record-high annual dividend of CHF 4.70 per share; impact estimated at ~2% as dividend is record-high, scheduled.
Annual General Meeting (2026-06-16) where shareholders will vote on proposals including the dividend; impact estimated at ~1% as it is a significant governance event, scheduled.
Hansoh Pharmaceutical will be added to the Hang Seng China Enterprises Index (HSCEI) on June 8, 2026; index inclusion typically triggers significant passive fund inflows scheduled.
Akeso Inc. is scheduled to be added to the Hang Seng China Enterprises Index (HSCEI) on June 8, 2026, following an announcement on May 22, 2026. High importance is estimated due to expected institutional capital inflows, scheduled.
Alphabet's quarterly cash dividend of $0.22 per share has an ex-dividend date of June 8, 2026. The dividend, representing a 5% increase, is payable on June 15, 2026, scheduled.
Fourth quarter and full-year fiscal 2026 earnings release on 2026-06-03 scheduled. High importance is assigned as earnings reports typically trigger significant price volatility; analysts forecast revenue of $9.6 billion and GAAP EPS of $1.20 forecasted.
Ex-dividend date on 2026-06-01 for a final dividend of RMB 0.5390 and a special dividend of RMB 0.6714 for FY2025, totaling RMB 1.2104 per share, scheduled. Medium importance is estimated based on the expected price adjustment on the ex-dividend date.
Akeso is scheduled to present Phase III HARMONi-6 study data for Ivonescimab at the ASCO Annual Meeting starting May 29, 2026. High importance is estimated as plenary session clinical data often drives significant price impact, scheduled.
Announced that CVS Caremark will restore preferred formulary coverage for its weight-loss drug Zepbound effective October 1, 2026, and add its oral drug Foundayo effective June 1, 2026, significantly expanding patient access. High importance is estimated due to the expected >10% price impact from increased market reach.
The company's subsidiary, Chia Tai Tianqing, announced that its innovative IDH1 inhibitor, TQB3454, was granted priority review by China's Center for Drug Evaluation (CDE) for the treatment of advanced biliary tract cancer on 2026-05-28. This is estimated to have a medium market impact of approximately 5% due to the potential for accelerated market entry.
Announced that its Class 1 innovative drug, Luzhunolei Sodium Tablets (SHR4640), was approved for marketing by the National Medical Products Administration of China. This is the first domestically developed high-selectivity URAT1 inhibitor for treating hyperuricemia in gout patients. This approval is expected to have a >=5% price impact due to the drug's market potential. expected
Announced that its subsidiary, Chongqing Yaoyou, entered into a licensing agreement with Genrix Biopharmaceutical for the rights to a bispecific antibody (GR1803) in the Greater China region.
CSPC reported Q1 2026 revenue of CNY 6.47 billion, down 7.8% YoY, and net profit of CNY 860 million, down 41.8% YoY. The decline was mainly due to a high base from licensing income in Q1 2025. The stock price fell over 10% on the day of the announcement.
CEO Mike Mahoney reiterated soft full-year guidance at the Bernstein Strategic Decisions Conference on 2026-05-27, flagging weaker demand for the key WATCHMAN device and in the urology franchise, resulting in a ~12% stock price drop.
XtalPi announced it received a second payment of USD 19 million from its collaboration partner DoveTree on May 27, 2026, as a pan-cancer asset from their collaboration entered the IND-enabling study stage.
The company announced positive Phase I clinical data for its liver-targeted THR-β agonist, Kylo-0603, for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) at the EASL 2026 Congress on 2026-05-27. This early-stage data is estimated to have a low market impact of approximately 1-2%.
On 2026-05-26, the company announced that the final analysis of its Phase III NEOTORCH study for toripalimab plus chemotherapy met its primary endpoints; a supplemental new drug application submission (Estimated >10% impact due to major clinical success in NSCLC) is expected.
The company announced on May 26, 2026, a plan to repurchase up to US$400 million of its shares on the open market, stating that the current share price does not reflect its intrinsic value.
Announced agreements on 2026-05-26 to acquire three vaccine development companies (Curevo, LimmaTech Biologics, Vaccine Company) for up to $3.83 billion to expand its pipeline into infectious diseases. High importance is estimated as this major acquisition is expected to have a >10% price impact.
Reports on May 26, 2026, indicated the European Union is preparing a significant fine against Google under the Digital Markets Act (DMA) for allegedly favoring its own services in search results. A decision is expected before the EU's summer break.
On May 26, 2026, 3SBio announced a proposal to appoint KPMG as its new auditor, replacing Ernst & Young, subject to shareholder approval at the upcoming Annual General Meeting (estimated ≥1% impact as auditor change is a routine corporate matter).
The company's co-founders voluntarily extended the lock-up period for their shares, totaling approximately 12.9% of the issued share capital, for an additional 12 months to June 12, 2027, as announced on May 25, 2026.